Search Results
389 results
Your search is now limited to «Bristol-Myers Squibb» expert search.
National Law Review 03/22/2019 13:26
Whole Foods recently requested information regarding the filing of class action lawsuits and whether the Bristol-Myers Squibb decision which limits jurisdictional state reach also applies to class actions.
More from National Law Review: 03/22/2019 09:15
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
More from
FiercePharmaManufacturing 03/21/2019 10:47
Prior to this week’s escalation of the war between Starboard and BMS, analysts, by and large, were predicting investors would vote thumbs-up on the Celgene deal in April.
More from FiercePharmaManufacturing:
Motley Fool 03/19/2019 21:33
Starboard Value owns a sliver of Bristol-Myers Squibb's outstanding shares, and the fund has zero enthusiasm for the deal.
More from Motley Fool:
ENDPOINTS 03/19/2019 10:24
Bristol-Myers Squibb execs and Starboard Value are back at it today, exchanging broadsides for and against the $74 billion buyout.
More from ENDPOINTS:
STAT 03/19/2019 09:32
Bristol-Myers Squibb (BMY) and Starboard Value issued dueling presentations over the merits of the $74 billion bid the drug maker has made for Celgene (CELG.
More from STAT:
PMLiVE 03/19/2019 08:57
Bristol-Myers Squibb is looking to convince investors that its $74bn takeover of Celgene is a sound move, ahead of a key shareholder vote on the deal.
More from PMLiVE: 03/19/2019 07:56
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (NASDAQ: CELG).
More from
PR Newswire 03/19/2019 07:00
Starboard also announced today that it has mailed definitive proxy materials and a BLUE proxy card in connection with the Company's Special Meeting of Shareholders scheduled to take place on April 12, 2019 , at which Bristol-Myers shareholders will vote on the issuance of shares of Bristol-Myers common stock pursuant to the Merger.
More from PR Newswire:
Business Wire 03/19/2019 06:59
Bristol-Myers Squibb urges shareholders to discard any blue proxy cards and disregard any related solicitation materials sent to you by Starboard Value LP, which is soliciting proxies from Bristol-Myers Squibb shareholders against approving the merger ...
More from Business Wire:
Seeking Alpha 03/18/2019 09:55
The news of Bristol-Myers Squibb (BMY) acquiring Celgene (CELG) immediately caused BMY stock to drop over 13% from $52.02 to $45.12 while Celgene shot up 21% from $66.64 to $80.43.
More from Seeking Alpha:
pharmaphorum 03/15/2019 07:57
Analysts said the decision could help clear the way for Bristol-Myers Squibb’s $74 billion takeover of Celgene.
More from pharmaphorum: 03/11/2019 18:14
Third Point holds Celgene stock, in bet Bristol-Myers deal will close: source.
More from
Forbes 03/11/2019 14:41
Bristol-Myers Squibb (NYSE:BMY) saw high single-digit top line growth in 2018, as strong growth in Eliquis and Opdivo sales more than offset the declines in its mature drugs portfolio. The bottom line grew in the low thirties percent, led by higher revenues, lower share count, and lower taxes....
More from Forbes:
3BL Media 03/11/2019 10:55
DESCRIPTION:. Bristol-Myers Squibb is excited to again be part of the 2019 NAFE Top Companies for Executive Women annual list. The company is committed to empowering women like Catherine Liu, Head of Finance, Intercon FP&A and South East Asia, through the development of female talent, career advancement and leadership opportunities at BMS. Learn more about the company’s inclusive culture . Tweet me: Bristol-Myers Squibb recognized for #empoweringwomen as a 2019 @_NAFE_ Top Company for Executive Women @BMSnews #diversity #inclusion #careers.
Market Exclusive 03/08/2019 07:08
To view the full exhibit click here About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.
More from Market Exclusive:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications